Carbon Monoxide’s Unique Mechanisms of Action

CO has been Validated by a Wide Variety of Clinical Trials

Over the last 25 years, research of carbon monoxide (“CO”) has strongly indicated that CO confers a variety of cytoprotective, anti-proliferative, anti-oxidant and anti-inflammatory effects. Two of the leadng inventors of most of the intellectual property involving therapeutic uses of gaseous CO are Augustine Choi, M.D. and David Pinsky, M.D., the two scientific co-founders of Proterris. Their body of work – amongst others – support the use of CO in a number of clinical indications pursued by Proterris.

A non-exhaustive summary of investigator CO clinical trials listed below illustrates the breadth of potential CO indications of interest to the clinical community

The iCO Delivery Device

Proterris’ inhaled CO therapies will be developed and commercialized as a combined CO drug – device product.  In order to safely and reliably deliver controlled quantities of CO, the iCO device pairs:

  • A CO Injector to mix CO into breathable air
  • An Inhaled Gas Monitoring Module to measure CO concentration and ensure correct dosing
  • A Patient Friendly Control Module to match breath rate and track doses 
  • Proterris is developing ventilator and spontaneous breathing versions for DGF and IPF indications, respectively
  • Design and clinical testing of the iCO device has been initiated as part of an ARDS NIH grant
  • Proterris’s device is technically identical to “First in Human” (FIH) device developed for the NIH ARDS trial with same source gas and dosing range capabilities.
  • Progress & experience gained during development of NIH-funded device reduces costs and technology risks for final Proterris devices

The Next Generation: CO-Releasing Molecules

CO-Releasing Molecules can Expand CO Therapy to Patients and Indications Not Suitable for Inhaled CO

Through a merger with Alfama, Inc., the leading company in the discovery and development of CORMs, Proterris controls a library of CORMs that:

  • Have varied CO release triggers and kinetics

  • Have a range of biodistributions and bioavailabilities

  • Are easily modifiable through medicinal chemistry

  • Are easily synthesized and inexpensive to produce